Clinical trials: Regorafenib
Gastro-Oesophageal Cancer
RegoNivo vs Standard of Care Chemotherapy in AGOC
To determine if the regorafenib and nivolumab combination (RegoNivo) improves overall survival compared with current standard chemotherapy options in refractory AGOC.
- Trial name
- INTEGRATEIIb (NCT04879368)
- Testing
- Regorafenib, Nivolumab, Docetaxel
- Where
- 94 sites in United States, Australia and 7 more
- Volunteers
- 462 people
- Sponsor
- Australasian Gastro-Intestinal Trials Group
Carcinoma, Hepatocellular, Hepatic Insufficien
Regorafenib After Treatment Failure of First Line Immune Checkpoint Inhibitor Treatment in Advanced Hepatocellular Carcinoma Patients
Immune checkpoint inhibitor (ICI)-based regimens (atezolizumab+bevacizumab, durvalumab+tremelimumab, nivolumab+ipilimumab) are now a first-line standard for advanced hepatocellular carcinoma (HCC).
- Conditions
- Carcinoma, Hepatocellular, Hepatic Insufficien, Disease Progression, Treatment Failure
- Trial name
- RECOMEND (NCT07514455)
- Testing
- Regorafenib (BAY 73-4506)
- Where
- South Korea
- Volunteers
- 20 people
- Sponsor
- Ju Hyun Shim
Hepatocellular Carcinoma Non-resectable
Combined TACE, TKI/Anti-VEGF and ICIs as Conversion Therapy for Advanced Hepatocellular Carcinoma
The aim of this study is to the efficacy, prognosis, adverse effects, and factors for predicting therapeutic effects and clinical prognosis of combined therapy of transarterial chemoembolization (TACE), Anti-VEGF antibodies or…
- Trial name
- CCGLC-008 (NCT05717738)
- Testing
- TACE, Lenvatinib, Anti-PD-1 monoclonal antibody
- Where
- 4 sites in China
- Volunteers
- 300 people
- Sponsor
- Tongji Hospital
Colorectal Neoplasms, Adenocarcinoma of the Colon
Study of Colorectal Cancer Patients (Stage IIIC) With Either Regorafenib or Standard of Care (No Treatment) After Adjuvant FOLFOX
This study, for patients who have Stage IIIC colorectal cancer and who underwent 5-fluorouracil/leucovorin with oxaliplatin (FOLFOX) chemotherapy after surgery, will test to see if regorafenib given after the completion of FOLFOX…
- Conditions
- Colorectal Neoplasms, Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum
- Trial name
- NCT02425683
- Testing
- Regorafenib
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- US Oncology Research
Colorectal Cancer
Metastatic Colorectal Cancer Treated With Regorafenib and FOLFIRI
The survey is a retrospective study to evaluate the prognotic value of EGFR expression, KRAS mutations and tumor sideness in patients with metastatic colorectal cancer treated with regorafenib and FOLFIRI as a third- or…
- Trial name
- NCT03698253
- Testing
- Regorafenib, UGT1A1 genotyping (TA6/TA6), UGT1A1 genotyping (TA6/TA7)
- Where
- Taiwan
- Volunteers
- 41 people
- Sponsor
- Kaohsiung Medical University Chung-Ho Memorial Hospital
Colorectal Neoplasms
Regorafenib in Subjects With Antiangiogenic-naive and Chemotherapy-refractory Advanced Colorectal Cancer
To determine the efficacy (as measured by progression-free survival [PFS] rate at 8 weeks) of regorafenib in subjects with metastatic colorectal cancer (CRC) whose disease is refractory to standard therapies and who were never…
- Trial name
- NCT02465502
- Testing
- Regorafenib (Stivarga, BAY73-4506)
- Where
- Brazil
- Volunteers
- 59 people
- Sponsor
- Bayer
Hepatocellular Carcinoma
Optimization for Regorafenib in HCC
This is a randomized, two arm, phase II study of 1st Cycle dose optimization for regorafenib treatment compared to standard dose of regorafenib treatment in HCC patients for whom the physician is intending to treat with…
- Trial name
- ReDos HCC (NCT04476329)
- Testing
- Regorafenib 40 MG
- Where
- 9 sites in United States
- Volunteers
- 7 people
- Sponsor
- SC Liver Research Consortium, LLC
Colorectal Neoplasms
SBRT Followed by PD-1 Inhibitor, Bevacizumab and TAS-102 as Third-Line Therapy for Recurrent/Metastatic Colorectal Cancer
This phase II trial studies how well stereotactic body radiotherapy (SBRT) followed by a combination of an immune checkpoint inhibitor (sintilimab), bevacizumab, and trifluridine/tipiracil (TAS-102) works as third-line treatment…
- Trial name
- BEST (NCT07535632)
- Testing
- SBRT, Sintilimab, Bevacizumab
- Where
- China
- Volunteers
- 58 people
- Sponsor
- Shanghai Zhongshan Hospital
Metastatic Colorectal Cancer
ctDNA-guided Treatment of TKI Plus PD-1 Inhibitor for Advanced pMMR/MSS Colorectal Cancer
The efficacy of combining TKI with PD-1 inhibitor in the treatment of advanced MSS/pMMR colorectal cancer with low levels of maxVAF in peripheral blood ctDNA failed with standard treatment was assessed, compared to standard…
- Trial name
- NCT06543836
- Testing
- Sintilimab, Fruquintinib or Regorafenib, Fruquintinib
- Where
- China
- Volunteers
- 68 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Recurrent Glioblastoma
Regorafenib in Bevacizumab Refractory Recurrent Glioblastoma
The purpose of this study is to determine the safety and tolerability of Regorafenib in patients with recurrent or progressive glioblastoma (GBM) who have progressed on bevacizumab.
- Trial name
- NCT04051606
- Testing
- Regorafenib
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Case Comprehensive Cancer Center
Neoplasms
Phase I Study of BAY73-4506 in Chinese Patients With Advanced, Refractory Solid Tumors
This will be an uncontrolled, open-label, non-randomized, phase I study. The primary objectives of this study are to define the pharmacokinetics (PK) and to evaluate the safety and tolerability of Regorafenib administered orally…
- Trial name
- NCT01096030
- Testing
- Regorafenib (Stivarga, BAY73-4506)
- Where
- 4 sites in Hong Kong, Singapore
- Volunteers
- 33 people
- Sponsor
- Bayer
Liver Cancer, Hepatocellular Carcinoma
Dose-escalation of Regorafenib in Advanced Hepatocellular Carcinoma
The present protocol (STRAT-aHCC trial) aims to prospectively evaluate the tolerability, quality of life and efficacy of an alternative regimen of regorafenib in patients with advanced hepatocellular carcinoma (HCC) after…
- Trial name
- STRAT-aHCC (NCT05622136)
- Testing
- Regorafenib Oral Product
- Where
- Brazil
- Volunteers
- 28 people
- Sponsor
- Instituto do Cancer do Estado de São Paulo
Colorectal Cancer Liver Metastases, Regorafenib
Regorafenib Combined With Irinotecan Drug-Eluting Beads for Colorectal Cancer Liver Metastases
This study is a multicentre, prospective, randomised trial, aims to evaluate the efficacy and safety of Irinotecan Drug-Eluting Beads combined with regorafenib as the third-line treatment for a patient with colorectal cancer…
- Trial name
- RIDER (NCT05794971)
- Testing
- Regorafenib and DIBIRI, Regorafenib
- Where
- China
- Volunteers
- 126 people
- Sponsor
- Sun Yat-sen University
Dietary Fats, Pharmacokinetics
The Effect of Food (High Fat and Low Fat Breakfast) on the Pharmacokinetics of Regorafenib
An open label, three way crossover study to determine the effect of a high fat breakfast or a low fat breakfast on the pharmacokinetics of a single dose of regorafenib.
- Trial name
- NCT01002378
- Testing
- Regorafenib (Stivarga, BAY73-4506)
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Bayer
Liver Metastases, Colorectal Cancer Metastatic
Cryoablation Combined with Sintilimab Plus Regorafenib in Previously Treated Colorectal Cancer Liver Metastasis
The objective of this study is to evaluate the efficacy and safety of cryoablation combined with Sintilimab plus regorafenib for patients with colorectal cancer liver metastasis in the third-line setting.
- Trial name
- NCT05057052
- Testing
- Sintilimab, Regorafenib, US/CT-guided Percutaneous Cryoablation
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Fudan University
MCRC
"Thymalfasin Immunotherapy Study with Triple Regimen in Advanced MSS/pMMR Colorectal Cancer"
This is a multicenter, open-label, prospective, randomized controlled Phase II clinical study. All eligible subjects will be randomly assigned in a 1:1 ratio to either the triple therapy group or the double therapy group.
- Trial name
- THYMI (NCT06829355)
- Testing
- Thymalfasin (Thymosin alpha 1, Ta1), Regorafenib (BAY 73-4506), Tislelizumab (BGB-A317)
- Where
- China
- Volunteers
- 52 people
- Sponsor
- Beijing Friendship Hospital
Metastatic Colorectal Cancer
Phase II Study of Perindopril and Regorafenib in mCRC
The purpose of this study is to find out what effects the combination of regorafenib and perindopril has on hand-foot skin reaction (HFSR), on high blood pressure (hypertension) and on any other types of side-effects and compare…
- Trial name
- PARICCA (NCT02651415)
- Testing
- Regorafenib, Perindopril
- Where
- Canada
- Volunteers
- 12 people
- Sponsor
- British Columbia Cancer Agency
Metastatic Colorectal Cancer
Regorafenib in Taiwan Metastatic Colorectal Cancer (mCRC) Patients
Regorafenib is currently the standard of care for refractory mCRC patients. Pivotal studies of regorafenib have proven the efficacy and safety, with a 28-day cycle (21 days on, 7 days off) and 160 mg dose given once daily.
- Trial name
- NCT03829852
- Testing
- Regorafenib
- Where
- Taiwan
- Volunteers
- 716 people
- Sponsor
- Taipei Veterans General Hospital, Taiwan
Gastrointestinal Stromal Tumors
Regorafenib Post-marketing Surveillance in Japan
The objective of this study is to assess safety and effectiveness of Regorafenib using in real clinical practice
- Trial name
- NCT01933958
- Testing
- Regorafenib (Stivarga, BAY73-4506)
- Where
- Japan
- Volunteers
- 72 people
- Sponsor
- Bayer
Liver Metastasis Colon Cancer
TACE Plus HAIC Combined With Regorafenib for Liver Metastasis of Colorectal Cancer Refractory to Standard Treatment Regimens
Liver metastasis is the main reason that affects the survival rates of patients with colorectal cancer (CRLM), and is also the main cause of death of those patients.
- Trial name
- DREAM (NCT06071052)
- Testing
- TACE and HAIC Combined With Regorafenib
- Where
- China
- Volunteers
- 21 people
- Sponsor
- First Affiliated Hospital, Sun Yat-Sen University